ZIPSTA Trademark

Trademark Overview


On Monday, February 20, 2012, a trademark application was filed for ZIPSTA with the United States Patent and Trademark Office. The USPTO has given the ZIPSTA trademark a serial number of 85547257. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 8, 2016. This trademark is owned by Eli Lilly and Company. The ZIPSTA trademark is filed in the Pharmaceutical Products category with the following description:

Veterinary preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; antibiotics for use in livestock; veterinary preparations for the treatment of enteric clostridium infections; veterinary preparations for the prevention of enteric clostridium infections; veterinary preparations in the treatment of Cushing's disease in animals; veterinary preparations for the control and symptomatic relief of viral and bacterial infectious diseases of cattle; immunorestorative biopharmaceutical for enhancing the immune system of cattle; veterinary preparations for controlling and destroying vermin, namely, insecticides and pesticides for use with poultry and livestock animals and poultry and livestock premises; veterinary preparations, namely, vaccines, antimicrobials and other medicinal drugs for the prevention, treatment, control, or symptomatic relief of infectious, non-infectious and metabolic diseases of poultry and livestock; animal feed supplements...
zipsta

General Information


Serial Number85547257
Word MarkZIPSTA
Filing DateMonday, February 20, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 8, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 6, 2012

Trademark Statements


Goods and ServicesVeterinary preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; antibiotics for use in livestock; veterinary preparations for the treatment of enteric clostridium infections; veterinary preparations for the prevention of enteric clostridium infections; veterinary preparations in the treatment of Cushing's disease in animals; veterinary preparations for the control and symptomatic relief of viral and bacterial infectious diseases of cattle; immunorestorative biopharmaceutical for enhancing the immune system of cattle; veterinary preparations for controlling and destroying vermin, namely, insecticides and pesticides for use with poultry and livestock animals and poultry and livestock premises; veterinary preparations, namely, vaccines, antimicrobials and other medicinal drugs for the prevention, treatment, control, or symptomatic relief of infectious, non-infectious and metabolic diseases of poultry and livestock; animal feed supplements; medicated feed and water additives for animals; veterinary preparations for food safety, namely, anti-microbial preparations for inhibiting microbiological decomposition in food and animal feed; veterinary preparations, namely, anti-microbials and vaccines for food safety and food animal processing; antibacterial pharmaceuticals; veterinary preparations for production improvement for poultry and livestock, namely, medicated feed additives for poultry and livestock and medicated water additives for poultry and livestock; diagnostic agents, tests, preparations and substances to identify pathogens or residues of biological interest for veterinary use; bactericides, namely, bacteriophage used as a human food safety agent to reduce levels of food borne pathogens carried on livestock or meat prior to being processed for human consumption; bacterial vector based vaccines relating to infection and non-infectious diseases or productivity loss in all avian, ruminant and swine species, the prevention or reduction of contamination of food produced by any or all avian, ruminant or swine species, the prevention of food-borne diseases in humans associated with contact with or consumption of food produced by any or all avian, ruminant or swine species; pathogen reduction preparations for pathogens that are in or on animals and that take the form of bacteria contaminants in meat which may be found in the livestock's digestive systems, or on the livestock during the harvest and processing phases; pathogen reduction treatment preparation for use on treating bacteria contaminants in meat which may be found in the livestock's digestive systems, or on the livestock during the harvest and processing phases; veterinary preparations containing natural plant extracts for oral administration to avian species and other livestock as an aid in managing health risks and productivity, namely, veterinary preparations for infection and non-infectious diseases or productivity loss in avian species and other livestock; Veterinary preparations for use in the treatment of fleas on pets; veterinary preparations for use in the prevention of fleas on pets; insecticides to prevent fleas on pets; transdermal drug delivery products for use on companion and food animals, namely, skin penetration medicine for pain and inflammation; veterinary preparations for companion animals in the treatment of parasitic infestations; transdermal topical solution administered by veterinarians in a surgical setting to treat pain in companion animals; veterinary preparations for companion animals in the treatment of anxiety, diabetes, hyperthyroidism, hypothyroidism, obesity, urine spraying, urinary incontinence; dental and oral disease, namely, stomatitis, Feline Odontoclastic Resorptive Lesion, periodontitis; veterinary preparations for companion animals in the treatment of chronic pain associated with osteoarthritis and cancer; veterinary preparations for companion animals in the treatment of gastrointestinal disorders associated with cholangiohepatitis, inflammatory bowel disorder, pancreatitis, gastritis, chronic colitis, enteritis; veterinary preparations for companion animals in the treatment of central nervous systems diseases and disorders, namely, cerebellar hypoplasia, cerebellar abiotrophy, laryngeal paralysis, meningoencephalitis, syringomyelia; veterinary preparations for companion animals in the treatment of neurological and neurodegenerative disorders, namely, seizure, epilepsy, neuropathies; veterinary preparations for companion animals in the treatment of parasitic infections and infestations associated with acaricides, heartworm, GI nematodes, mange, fleas; veterinary preparations for companion animals in the treatment of cardiovascular conditions namely, hypertension, cardiomyopathies, hear murmurs, heart failure; veterinary preparations for companion animals in the treatment of dermatologic conditions, namely, canine atopic dermatitis, skin rash, flea allergy, food allergy, cancer; veterinary preparations for companion animals in the treatment of chronic kidney disease and associated conditions namely, anemia, hyperphosphatemia, hypocalcemia, hypertension, cachexia; veterinary preparations for companion animals in the treatment of acute pain associated with orthopedic and soft tissue surgery, trauma, and musculoskeletal conditions; veterinary preparations for companion animals in the treatment of osteoarthritis, otitis and wound healing; veterinary preparations for companion animals in the treatment of infections, namely, upper respiratory; veterinary preparations for companion animals in the treatment of allergy atopic conditions associated with atopic dermatitis, seasonal allergies, asthma; veterinary preparations for companion animals in the treatment of liver disease, acute and chronic hepatitis; nonsurgical sterilization

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 27, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, February 8, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, February 8, 2016ABANDONMENT - NO USE STATEMENT FILED
Friday, July 10, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 9, 2015EXTENSION 5 GRANTED
Friday, June 26, 2015EXTENSION 5 FILED
Friday, June 26, 2015TEAS EXTENSION RECEIVED
Wednesday, December 17, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 16, 2014EXTENSION 4 GRANTED
Friday, December 12, 2014EXTENSION 4 FILED
Friday, December 12, 2014TEAS EXTENSION RECEIVED
Tuesday, June 17, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 16, 2014EXTENSION 3 GRANTED
Tuesday, June 10, 2014EXTENSION 3 FILED
Tuesday, June 10, 2014TEAS EXTENSION RECEIVED
Tuesday, February 11, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 10, 2014EXTENSION 2 GRANTED
Monday, December 16, 2013EXTENSION 2 FILED
Friday, January 31, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 16, 2013TEAS EXTENSION RECEIVED
Thursday, May 30, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 28, 2013EXTENSION 1 GRANTED
Tuesday, May 28, 2013EXTENSION 1 FILED
Tuesday, May 28, 2013TEAS EXTENSION RECEIVED
Tuesday, January 1, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 6, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 6, 2012PUBLISHED FOR OPPOSITION
Wednesday, October 17, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 1, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, September 13, 2012ASSIGNED TO LIE
Tuesday, September 4, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, September 1, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 31, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 31, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 28, 2012NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 28, 2012NON-FINAL ACTION E-MAILED
Wednesday, March 28, 2012NON-FINAL ACTION WRITTEN
Friday, March 23, 2012ASSIGNED TO EXAMINER
Monday, February 27, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, February 23, 2012NEW APPLICATION ENTERED IN TRAM